Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 20;14(16):4027. doi: 10.3390/cancers14164027

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Effects of dasatinib, trametinib, and their combination on the viability and morphology of MDA-MB-231 cells. (a) Cell viability was determined after MDA-MB-231 cells were treated with dasatinib, trametinib, and their combination at equimolar concentrations for 48 h. (b) The relationship between the dose-reduction index (DRI) and the percentage of inhibition. (c) MDA-MB-231 cell morphology at the end of treatment with dasatinib, trametinib, and their combination (1 μM). (d) Comparison between MDA-MB-231 and MDA-MB-468 in the dose–response to dasatinib/trametinib combination.